BR0015995A - Compostos 2,4-diaminopirimidina úteis como imunossupressores - Google Patents

Compostos 2,4-diaminopirimidina úteis como imunossupressores

Info

Publication number
BR0015995A
BR0015995A BR0015995-6A BR0015995A BR0015995A BR 0015995 A BR0015995 A BR 0015995A BR 0015995 A BR0015995 A BR 0015995A BR 0015995 A BR0015995 A BR 0015995A
Authority
BR
Brazil
Prior art keywords
compounds useful
immunosuppressants
compounds
diaminopyrimidine compounds
diaminopyrimidine
Prior art date
Application number
BR0015995-6A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Eileen Elliot Mueller
Eric Jan Roskamp
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0015995A publication Critical patent/BR0015995A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

"COMPOSTOS 2,4-DIAMINOPIRIMIDINA úTEIS COMO IMUNOSSUPRESSORES". Compostos de acordo com a fórmula (I) e seus sais, solvatos, ou hidratos farmaceuticamente aceitáveis; em que cada ocorrência de A é independentemente selecionada de CH ou N; X é selecionado do grupo consistindo de -CH~ 2~-, -O-, -NH-, (C~ 1~C~ 6~ ) alquilamino, (C~ 1~-C~ 6~ ) alquilaminocarbonilamino-, (ciC6)a lquilcarbonilamino-, (C ,-C 6)alquilsulfonilamino-, fenilsulfonilamino-, carbonila, -NH-C(O)-, -N(C~ 1~-C~ 6~ ) alquil-C(O)-, -S(O)~ y~- onde y é 0, 1 ou 2, e; n em -(CH~ 2~ )~ n~- é 1, 2 ou 3; e R^ 1^, R^ 2^, e R^ 3^ são como aqui descritos; composições farmacêuticas que incluem estes compostos, e métodos para o tratamento da doença auto-imune, inflamação, alergia, rejeição de transplante, e outras circunstâncias onde a administração de um agente imunossupressor é um benefício terapêutico.
BR0015995-6A 1999-11-30 2000-11-09 Compostos 2,4-diaminopirimidina úteis como imunossupressores BR0015995A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30
PCT/IB2000/001628 WO2001040215A1 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds usful as immunosuppressants

Publications (1)

Publication Number Publication Date
BR0015995A true BR0015995A (pt) 2002-08-06

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015995-6A BR0015995A (pt) 1999-11-30 2000-11-09 Compostos 2,4-diaminopirimidina úteis como imunossupressores

Country Status (33)

Country Link
EP (1) EP1242403B1 (pt)
JP (1) JP3955468B2 (pt)
KR (1) KR20020059826A (pt)
CN (1) CN1402720A (pt)
AP (1) AP2002002530A0 (pt)
AT (1) ATE315036T1 (pt)
AU (1) AU1047601A (pt)
BG (1) BG106695A (pt)
BR (1) BR0015995A (pt)
CA (1) CA2392971C (pt)
CO (1) CO5261519A1 (pt)
CZ (1) CZ20021703A3 (pt)
DE (1) DE60025385T2 (pt)
EA (1) EA200200411A1 (pt)
EE (1) EE200200275A (pt)
ES (1) ES2253266T3 (pt)
GT (1) GT200000200A (pt)
HN (1) HN2000000264A (pt)
HU (1) HUP0203300A3 (pt)
IL (1) IL149103A0 (pt)
IS (1) IS6339A (pt)
MA (1) MA26846A1 (pt)
MX (1) MXPA02005350A (pt)
NO (1) NO20022557D0 (pt)
OA (1) OA12097A (pt)
PA (1) PA8506801A1 (pt)
PE (1) PE20010900A1 (pt)
PL (1) PL355946A1 (pt)
SV (1) SV2002000231A (pt)
TN (1) TNSN00232A1 (pt)
TR (1) TR200201431T2 (pt)
UY (1) UY26455A1 (pt)
WO (1) WO2001040215A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
EA200300205A1 (ru) * 2000-08-31 2003-06-26 Пфайзер Продактс Инк. Производные пиразола и их применение в качестве ингибиторов протеинкиназы
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422377C (en) 2000-09-15 2010-04-13 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1345922B1 (en) 2000-12-21 2006-05-31 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
KR20050032105A (ko) 2002-08-02 2005-04-06 버텍스 파마슈티칼스 인코포레이티드 Ｇｓｋ-3의 억제제로서 유용한 피라졸 조성물
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
KR20060133552A (ko) * 2004-01-16 2006-12-26 노파르티스 아게 2,4-디아미노피리미딘 및 심장근육발생 유도를 위한 그의용도
ATE512144T1 (de) * 2004-10-12 2011-06-15 Decode Genetics Ehf Peri-substituierte bicyclische arylsulfonamide gegen arterielle verschlusskrankheiten
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
KR20080095902A (ko) 2006-02-14 2008-10-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀
AU2007227602A1 (en) * 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
BRPI0818338A2 (pt) * 2007-10-16 2015-04-22 Daiichi Sankyo Co Ltd Composto de pirimidil indolina
RU2012116526A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения производных пиримидина, применимых в качестве ингибиторов протеинкиназы
RU2012116525A (ru) 2009-09-25 2013-10-27 Вертекс Фармасьютикалз Инкорпорейтед Способы получения перемидиновых производных, пригодных в качестве ингибиторов протеинкиназ
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
WO2015054317A1 (en) 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
WO2019000683A1 (zh) 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
US11390609B2 (en) 2017-06-30 2022-07-19 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
ES2930804T3 (es) 2017-06-30 2022-12-22 Beijing Tide Pharmaceutical Co Ltd Inhibidor de proteína cinasa asociada a RHO, composición farmacéutica que lo comprende, así como método de preparación y uso del mismo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
ATE315036T1 (de) 2006-02-15
TR200201431T2 (tr) 2002-09-23
DE60025385T2 (de) 2006-08-24
PA8506801A1 (es) 2002-04-25
NO20022557L (no) 2002-05-29
AU1047601A (en) 2001-06-12
IL149103A0 (en) 2002-11-10
HUP0203300A3 (en) 2003-10-28
CN1402720A (zh) 2003-03-12
MXPA02005350A (es) 2002-12-11
OA12097A (en) 2006-05-04
DE60025385D1 (de) 2006-03-30
JP2003515602A (ja) 2003-05-07
AP2002002530A0 (en) 2002-06-30
WO2001040215A1 (en) 2001-06-07
KR20020059826A (ko) 2002-07-13
PL355946A1 (en) 2004-05-31
EP1242403A1 (en) 2002-09-25
NO20022557D0 (no) 2002-05-29
EA200200411A1 (ru) 2002-10-31
HUP0203300A2 (hu) 2003-02-28
GT200000200A (es) 2002-05-23
HN2000000264A (es) 2001-05-21
PE20010900A1 (es) 2001-09-08
EE200200275A (et) 2003-10-15
MA26846A1 (fr) 2004-12-20
CA2392971C (en) 2008-10-07
ES2253266T3 (es) 2006-06-01
IS6339A (is) 2002-04-12
SV2002000231A (es) 2002-07-16
BG106695A (bg) 2002-12-29
CA2392971A1 (en) 2001-06-07
CZ20021703A3 (cs) 2003-06-18
UY26455A1 (es) 2001-07-31
JP3955468B2 (ja) 2007-08-08
CO5261519A1 (es) 2003-03-31
EP1242403B1 (en) 2006-01-04
TNSN00232A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
BR0015995A (pt) Compostos 2,4-diaminopirimidina úteis como imunossupressores
BR9806413A (pt) Composto e uso do mesmo
ES2194181T3 (es) Derivados de quinazolina como inhibidores de vegf.
BR0210507A (pt) Azaindóis
ES2185307T3 (es) Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
ES2178037T3 (es) Derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.
CL2004000590A1 (es) Compuestos derivados de 1,3,4-oxadiazol-3-ona, 1,3,4-tiadiazol-2-ona y de 1,2,4-triazol-3-ona; composicion farmaceutica que los contiene; procedimiento de preparacion y su uso en la preparacion de un medicamento en los que esta relacionado el virus v
AR023823A1 (es) Compuestos derivados de piperazina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos.
BR0306214A (pt) Composto de 4-oxoquinolina e uso deste como inibidor de integrase de hiv
GEP20002211B (en) Taxoids, Preparation Thereof, Pharmaceutical Compositions Containing Same
ATE218582T1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
ES2061848T3 (es) Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
PA8435001A1 (es) Derivados 6,6-heterobiciclicos sustituidos.
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
BR0306811A (pt) Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
BR0215650A (pt) Preparação combinada para a administração simultânea, separada, ou sequencial no tratamento do câncer, método para o tratamento do câncer, uso de pelo menos um composto, e, composição farmacêutica
BRPI0412502A (pt) derivados de ariltiouréia substituìda úteis como inibidores de replicação viral
HUP0103431A2 (hu) 5-HT4 receptor agonista vagy antagonista hatóanyagot tartalmazó, orális gyógyászati készítmény
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
HUP0203226A2 (hu) Hatóanyagként benzamidszármazékot tartalmazó gyógyszerkészítmény
ES2134928T3 (es) Derivado de benzotiazolsulfonamida, procedimiento de produccion y aplicacion del mismo.
BR0211025A (pt) Um novo composto para o tratamento da impotência
DK0561882T3 (da) Hydroxamsyrederivater, som inhiberer lipoxygenase

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 10(VIII), 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.